Access cutting-edge atopic dermatitis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access atopic dermatitis specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related atopic dermatitis treatment provided free
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Sponsor: Eli Lilly and Company
Check if you qualify for this atopic dermatitis clinical trial in Chicago, IL
If you're searching for atopic dermatitis treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.